Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response

Virulence

Volumn 4, Issue 4, 2013, Pages 273-283

  Grant, Sarah Schmidt ^a,b,c   Hung, Deborah T ^a,b,c,d  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antibiotic tolerance; Biofilms; Oxidative stress; Persistent bacterial infections; Persisters; Small colony variants

Indexed keywords

ANTIBIOTIC AGENT; REACTIVE NITROGEN SPECIES;

ANTIBIOTIC SENSITIVITY; ASYMPTOMATIC INFECTION; BACTERIAL GROWTH; BACTERIAL INFECTION; BIOFILM; CELL SURVIVAL; CHEMOTHERAPY; CYSTIC FIBROSIS; ENDOTHELIUM CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; MACROPHAGE; MONOCYTE; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERSISTENT INFECTION; PHAGOLYSOSOME; REVIEW; SYPHILIS; T LYMPHOCYTE;

EID: 84878098314     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.23987     Document Type: Review

References (120)

1. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004; 84:29-44; PMID:14670344; http://dx.doi.org/10.1016/j.tube.2003.08.003
2. Monack DM, Mueller A, Falkow S. Persistent bacterial infections: the interface of the pathogen and the host immune system. Nat Rev Microbiol 2004; 2:747-765; PMID:15372085; http://dx.doi.org/10.1038/nrmi-cro955
3. Mcdermott W. Microbial persistence. Yale J Biol Med 1958; 30:257-291; PMID:13531168.
4. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007; 130:797-810; PMID:17803904; http://dx.doi.org/10.1016/j.cell.2007.06.049
5. Dwyer DJ, Kohanski MA, Hayete B, Collins JJ. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Mol Syst Biol 2007; 3:91; PMID:17353933; http://dx.doi.org/10.1038/msb4100135
6. Wang X, Zhao X. Contribution of oxidative damage to antimicrobial lethality. Antimicrob Agents Chemother 2009; 53:1395-1402; PMID:19223646; http://dx.doi.org/10.1128/AAC.01087-08
7. Kolodkin-Gal I, Sat B, Keshet A, Engelberg-Kulka H. The communication factor EDF and the toxin-antitoxin module mazEF determine the mode of action of antibiotics. PLoS Biol 2008; 6:e319; PMID:19090622; http://dx.doi.org/10.1371/journal.pbio.0060319
8. Liu Y, Imlay JA. Cell death from antibiotics without the involvement of reactive oxygen species. Science 2013; 339:1210-1213; PMID:23471409; http://dx.doi.org/10.1126/science.1232751
9. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 2013; 339:1213-1216; PMID:23471410; http://dx.doi.org/10.1126/sci-ence.1232688
10. Lafond RE, Lukehart SA. Biological basis for syphilis. Clin Microbiol Rev 2006; 19:29-49; PMID:16418521; http://dx.doi.org/10.1128/CMR.19.1.29-49.2006
11. Kent ME, Romanelli F. Reexamining syphilis: an update on epidemiology, clinical manifestations, and management. Ann Pharmacother 2008; 42:226-236; PMID:18212261; http://dx.doi.org/10.1345/aph.1K086
12. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338:1175-1176; PMID:1682595; http://dx.doi.org/10.1016/0140-6736(91)92035-Z
13. Nomura A, Stemmermann GN, Chyou PH, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994; 120:977-981; PMID:7741826.
14. Caygill C P, Hill MJ, Braddick M, Sharp JC. Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet 1994; 343:83-84; PMID:7903779; http://dx.doi.org/10.1016/S0140-6736(94)90816-8
15. Bryers JD. Medical biofilms. Biotechnol Bioeng 2008; 100:1-18; PMID:18366134; http://dx.doi.org/10.1002/bit.21838
16. Lentino JR. Prosthetic joint infections: bane of orthopedists, challenge for infectious disease specialists. Clin Infect Dis 2003; 36:1157-1161; PMID:12715311; http://dx.doi.org/10.1086/374554
17. Shuman EK, Urquhart A, Malani PN. Management and prevention of prosthetic joint infection. Infect Dis Clin North Am 2012; 26:29-39; PMID:22284374; http://dx.doi.org/10.1016/j.idc.2011.09.011
18. Sculco T.P. The economic impact of infected joint arthroplasty. Orthopedics 1995; 18:871-873; PMID:8570494.
19. Fux CA, Stoodley P, Hall-Stoodley L, Costerton JW. Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther 2003; 1:667-683; PMID:15482163; http://dx.doi.org/10.1586/14787210.1.4.667
20. Lane RK, Matthay MA. Central line infections. Curr Opin Crit Care 2002; 8:441-448; PMID:12357113; http://dx.doi.org/10.1097/00075198-200210000-00012
21. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002; 15:194-222; PMID:11932230; http://dx.doi.org/10.1128/CMR.15.2.194-222.2002
22. Hunstad DA, Justice SS. Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli. Annu Rev Microbiol 2010; 64:203-221; PMID:20825346; http://dx.doi.org/10.1146/annurev.micro.112408.134258
23. Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health 1990; 80:331-333; PMID:2305919; http://dx.doi.org/10.2105/AJPH.80.3.331
24. Hooton TM. Recurrent urinary tract infection in women. Int J Antimicrob Agents 2001; 17:259-268; PMID:11295405; http://dx.doi.org/10.1016/S0924-8579(00)00350-2
25. Brown DL, Frank JE. Diagnosis and management of syphilis. Am Fam Physician 2003; 68:283-290; PMID:12892348.
26. Crawford RW, Rosales-Reyes R, Ramírez-Aguilar MdeL, Chapa-Azuela O, Alpuche-Aranda C, Gunn JS. Gallstones play a significant role in Salmonella spp. gallbladder colonization and carriage. Proc Natl Acad Sci U S A 2010; 107:4353-4358; PMID:20176950; http://dx.doi.org/10.1073/pnas.1000862107
27. von Eiff C, Jansen B, Kohnen W, Becker K. Infections associated with medical devices: patho-genesis, management and prophylaxis. Drugs 2005; 65:179-214; PMID:15631541; http://dx.doi.org/10.2165/00003495-200565020-00003
28. Parsek MR, Singh PK. Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol 2003; 57:677-701; PMID:14527295; http://dx.doi.org/10.1146/annurev.micro.57.030502.090720
29. Gonzalez-Escobedo G, Marshall JM, Gunn JS. Chronic and acute infection of the gall bladder by Salmonella Typhi: understanding the carrier state. Nat Rev Microbiol 2011; 9:9-14; PMID:21113180; http://dx.doi.org/10.1038/nrmicro2490
30. Otto M. Bacterial evasion of antimicrobial peptides by biofilm formation. Curr Top Microbiol Immunol 2006; 306:251-258; PMID:16909925; http://dx.doi.org/10.1007/3-540-29916-5_10
31. Ward KH, Olson ME, Lam K, Costerton JW. Mechanism of persistent infection associated with peritoneal implants. J Med Microbiol 1992; 36:406-413; PMID:1613780; http://dx.doi.org/10.1099/00222615-36-6-406
32. Shiau AL, Wu CL. The inhibitory effect of Staphylococcus epidermidis slime on the phagocytosis of murine peritoneal macrophages is interferon-independent. Microbiol Immunol 1998; 42:33-40; PMID:9525777.
33. Yasuda H, Ajiki Y, Aoyama J, Yokota T. Interaction between human polymorphonuclear leucocytes and bacteria released from in-vitro bacterial biofilm models. J Med Microbiol 1994; 41:359-367; PMID:7966209; http://dx.doi.org/10.1099/00222615-41-5-359
34. Nix RN, Altschuler SE, Henson PM, Detweiler CS. Hemophagocytic macrophages harbor Salmonella enterica during persistent infection. PLoS Pathog 2007; 3:e193; PMID:18085823; http://dx.doi.org/10.1371/journal.ppat.0030193
35. Anderl JN, Franklin MJ, Stewart PS. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 2000; 44:1818-1824; PMID:10858336; http://dx.doi.org/10.1128/AAC.44.7.1818-1824.2000
36. rd, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxa-cin and tobramycin. Antimicrob Agents Chemother 2003; 47:317-323; PMID:12499208; http://dx.doi.org/10.1128/AAC.47.1.317-323.2003
37. Anderson GG, O'Toole GA. Innate and induced resistance mechanisms of bacterial biofilms. Curr Top Microbiol Immunol 2008; 322:85-105; PMID:18453273; http://dx.doi.org/10.1007/978-3-540-75418-3_5
38. Barclay WRER, Ebert RH, Le Roy GV, Manthei RW, Roth LJ. Distribution and excretion of radioactive iso-niazid in tuberculous patients. J Am Med Assoc 1953; 151:1384-1388; PMID:13034481.
39. McCune RM, Feldmann FM, McDermott W. Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J Exp Med 1966; 123:469-486; PMID:4957011; http://dx.doi.org/10.1084/jem.123.3.469
40. Tomasz A, de Vegvar ML. Construction of a penicillin-tolerant laboratory mutant of Staphylococcus aureus. Eur J Clin Microbiol 1986; 5:710-713; PMID:3803383; http://dx.doi.org/10.1007/BF02013310
41. Helaine S, Thompson JA, Watson KG, Liu M, Boyle C, Holden DW. Dynamics of intracellular bacterial replication at the single cell level. Proc Natl Acad Sci U S A 2010; 107:3746-3751; PMID:20133586; http://dx.doi.org/10.1073/pnas.1000041107
42. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 2007; 4:e329; PMID:18092884; http://dx.doi.org/10.1371/journal.pmed.0040329
43. Justice SS, Hung C, Theriot JA, Fletcher DA, Anderson GG, Footer MJ, et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci U S A 2004; 101:1333-1338; PMID:14739341; http://dx.doi.org/10.1073/pnas.0308125100
44. Blango MG, Mulvey MA. Persistence of uropatho-genic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother 2010; 54:1855-1863; PMID:20231390; http://dx.doi.org/10.1128/AAC.00014-10
45. Mysorekar IU, Hultgren SJ. Mechanisms of uro-pathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci U S A 2006; 103:14170-14175; PMID:16968784; http://dx.doi.org/10.1073/pnas.0602136103
46. Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 2010; 6:e1001042; PMID:20811584; http://dx.doi.org/10.1371/journal.ppat.1001042
47. Russell DG. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunol Rev 2011; 240:252-268; PMID:21349098; http://dx.doi.org/10.1111/j.1600-065X.2010.00984.x
48. Sullivan J T, Young E F, McCann JR, Braunstein M. The Mycobacterium tuberculosis SecA2 system subverts phagosome maturation to promote growth in macrophages. Infect Immun 2012; 80:996-1006; PMID:22215736;http://dx.doi.org/10.1128/IAI.05987-11
49. MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003; 302:654-659; PMID:14576437; http://dx.doi.org/10.1126/science.1088063
50. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, et al. Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. J Exp Med 2003; 198:693-704; PMID:12953091; http://dx.doi.org/10.1084/jem.20030846
51. Ehrt S, Schnappinger D. Mycobacterial survival strategies in the phagosome: defence against host stresses. Cell Microbiol 2009; 11:1170-1178; PMID:19438516; http://dx.doi.org/10.1111/j.1462-5822.2009.01335.x
52. Edwards KM, Cynamon MH, Voladri RK, Hager CC, DeStefano MS, Tham KT, et al. Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2001; 164:2213-2219; PMID:11751190.
53. Ng VH, Cox JS, Sousa AO, MacMicking JD, McKinney JD. Role of KatG catalase-peroxidase in mycobacterial pathogenesis: countering the phagocyte oxidative burst. Mol Microbiol 2004; 52:1291-1302; PMID:15165233; http://dx.doi.org/10.1111/j.1365-2958.2004.04078.x
54. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, et al. Drug tolerance in replicating mycobacteria mediated by a macro-phage-induced efflux mechanism. Cell 2011; 145:39-53; PMID:21376383; http://dx.doi.org/10.1016/j.cell.2011.02.022
55. Ramón-García SMC, Martín C, Thompson CJ, Aínsa JA. Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob Agents Chemother 2009; 53:3675-3682; PMID:19564371; http://dx.doi.org/10.1128/AAC.00550-09
56. Poole K. Bacteria multidrug efflux pumps serve other functions. Microbes 2008; 3:179-185.
57. Tuchscherr L, Medina E, Hussain M, Völker W, Heitmann V, Niemann S, et al. Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. EMBO Mol Med 2011; 3:129-141; PMID:21268281; http://dx.doi.org/10.1002/emmm.201000115
58. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 2006; 4:295-305; PMID:16541137; http://dx.doi.org/10.1038/nrmicro1384
59. Starkey M, Hickman JH, Ma L, Zhang N, De Long S, Hinz A, et al. Pseudomonas aeruginosa rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung. J Bacteriol 2009; 191:3492-3503; PMID:19329647; http://dx.doi.org/10.1128/JB.00119-09
60. Kahl B, Herrmann M, Everding AS, Koch HG, Becker K, Harms E, et al. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 1998; 177:1023-1029; PMID:9534977; http://dx.doi.org/10.1086/515238
61. Häussler S, Tümmler B, Weissbrodt H, Rohde M, Steinmetz I. Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin Infect Dis 1999; 29:621-625; PMID:10530458; http://dx.doi.org/10.1086/598644
62. McNamara PJ, Proctor RA. Staphylococcus aureus small colony variants, electron transport and persistent infections. Int J Antimicrob Agents 2000; 14:117-122; PMID:10720801; http://dx.doi.org/10.1016/S0924-8579(99)00170-3
63. Bulger RJ, Bulger RE. Ultrastructure of small colony variants of a methicillin-resistant Staphylococcus aure-us. J Bacteriol 1967; 94:1244-1246; PMID:5183077.
64. Moisan H, Brouillette E, Jacob CL, Langlois-Bégin P, Michaud S, Malouin F. Transcription of virulence factors in Staphylococcus aureus small-colony variants isolated from cystic fibrosis patients is influenced by SigB. J Bacteriol 2006; 188:64-76; PMID:16352822; http://dx.doi.org/10.1128/JB.188.1.64-76.2006
65. Tuchscherr L, Heitmann V, Hussain M, Viemann D, Roth J, von Eiff C, et al. Staphylococcus aureus small-colony variants are adapted phenotypes for intra-cellular persistence. J Infect Dis 2010; 202:1031-1040; PMID:20715929; http://dx.doi.org/10.1086/656047
66. Balwit JM, van Langevelde P, Vann JM, Proctor RA. Gentamicin-resistant menadione and hemin auxotrophic Staphylococcus aureus persist within cultured endothelial cells. J Infect Dis 1994; 170:1033-1037; PMID:7930701; http://dx.doi.org/10.1093/infdis/170.4.1033
67. Schröder A, Kland R, Peschel A, von Eiff C, Aepfelbacher M. Live cell imaging of phagosome maturation in Staphylococcus aureus infected human endo-thelial cells: small colony variants are able to survive in lysosomes. Med Microbiol Immunol 2006; 195:185-194; PMID:16596413; http://dx.doi.org/10.1007/s00430-006-0015-0
68. von Eiff C, Heilmann C, Proctor RA, Woltz C, Peters G, Götz F. A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly. J Bacteriol 1997; 179:4706-4712; PMID:9244256.
69. von Eiff C, Becker K, Metze D, Lubritz G, Hockmann J, Schwarz T, et al. Intracellular persistence of Staphylococcus aureus small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with darier's disease. Clin Infect Dis 2001; 32:1643-1647; PMID:11340539; http://dx.doi.org/10.1086/320519
70. Sendi P, Proctor RA. Staphylococcus aureus as an intracellular pathogen: the role of small colony variants. Trends Microbiol 2009; 17:54-58; PMID:19162480; http://dx.doi.org/10.1016/j.tim.2008.11.004
71. Kahl BC, Belling G, Becker P, Chatterjee I, Wardecki K, Hilgert K, et al. Thymidine-dependent Staphylococcus aureus small-colony variants are associated with extensive alterations in regulator and virulence gene expression profiles. Infect Immun 2005; 73:4119-4126; PMID:15972501; http://dx.doi.org/10.1128/IAI.73.7.4119-4126.2005
72. Cui L, Neoh HM, Iwamoto A, Hiramatsu K. Coordinated phenotype switching with large-scale chromosome flip-flop inversion observed in bacteria. Proc Natl Acad Sci U S A 2012; 109:E1647-E1656; PMID:22645353; http://dx.doi.org/10.1073/pnas.1204307109
73. Chuard C, Vaudaux PE, Proctor RA, Lew D P. Decreased susceptibility to antibiotic killing of a stable small colony variant of Staphylococcus aureus in fluid phase and on fibronectin-coated surfaces. J Antimicrob Chemother 1997; 39:603-608; PMID:9184359; http://dx.doi.org/10.1093/jac/39.5.603
74. Imlay JA. Cellular defenses against superoxide and hydrogen peroxide. Annu Rev Biochem 2008; 77:755-776; PMID:18173371; http://dx.doi.org/10.1146/annurev.biochem.77.061606.161055
75. Hobby GLMK, Chaffee E. Observations of the mechanism of action of penicillin. Proc Soc Exp Biol Med 1942; 50:281-285.
76. Bigger J W. Treatment of staphylococcal infections with penicillin. Lancet 1944; 244:497-500; http://dx.doi.org/10.1016/S0140-6736(00)74210-3
77. Keren I, Shah D, Spoering A, Kaldalu N, Lewis K. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J Bacteriol 2004; 186:8172-8180; PMID:15576765; http://dx.doi.org/10.1128/JB.186.24.8172-8180.2004
78. Wood DN, Chaussee MA, Chaussee MS, Buttaro BA. Persistence of Streptococcus pyogenes in stationary-phase cultures. J Bacteriol 2005; 187:3319-3328; PMID:15866916; http://dx.doi.org/10.1128/JB.187.10.3319-3328.2005
79. Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 2007; 5:48-56; PMID:17143318; http://dx.doi.org/10.1038/nrmicro1557
80. Moyed HS, Bertrand K P. HipA, a newly recognized gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis. J Bacteriol 1983; 155:768-775; PMID:6348026.
81. Schumacher MA, Piro KM, Xu W, Hansen S, Lewis K, Brennan RG. Molecular mechanisms of HipA-mediated multidrug tolerance and its neutralization by HipB. Science 2009; 323:396-401; PMID:19150849; http://dx.doi.org/10.1126/science.1163806
82. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a phenotypic switch. Science 2004; 305:1622-1625; PMID:15308767; http://dx.doi.org/10.1126/science.1099390
83. Keren I, Minami S, Rubin E, Lewis K. Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters. MBio 2011; 2:e00100-e00111; PMID:21673191; http://dx.doi.org/10.1128/mBio.00100-11
84. Maisonneuve E, Shakespeare LJ, Jørgensen MG, Gerdes K. Bacterial persistence by RNA endonucle-ases. Proc Natl Acad Sci U S A 2011; 108:13206-131211; PMID:21788497; http://dx.doi.org/10.1073/pnas.1100186108
85. Gerdes K, Maisonneuve E. Bacterial persistence and toxin-antitoxin loci. Annu Rev Microbiol 2012; 66:103-123; PMID:22994490; http://dx.doi.org/10.1146/annurev-micro-092611-150159
86. Wakamoto Y, Dhar N, Chait R, Schneider K, Signorino-Gelo F, Leibler S, et al. Dynamic persistence of antibiotic-stressed mycobacteria. Science 2013; 339:91-95; PMID:23288538; http://dx.doi.org/10.1126/science.1229858
87. Kim JS, Heo P, Yang TJ, Lee KS, Jin YS, Kim SK, et al. Bacterial persisters tolerate antibiotics by not producing hydroxyl radicals. Biochem Biophys Res Commun 2011; 413:105-110; PMID:21872573; http://dx.doi.org/10.1016/j.bbrc.2011.08.063
88. Miller C, Thomsen LE, Gaggero C, Mosseri R, Ingmer H, Cohen SN. SOS response induction by beta-lac-tams and bacterial defense against antibiotic lethality. Science 2004; 305:1629-1631; PMID:15308764; http://dx.doi.org/10.1126/science.1101630
89. Dörr T, Vulic M, Lewis K. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol 2010; 8:e1000317; PMID:20186264; http://dx.doi.org/10.1371/journal.pbio.1000317
90. Dörr T, Lewis K, Vulic M. SOS response induces persistence to fluoroquinolones in Escherichia coli. PLoS Genet 2009; 5:e1000760; PMID:20011100; http://dx.doi.org/10.1371/journal.pgen.1000760
91. Lee HH, Molla MN, Cantor CR, Collins JJ. Bacterial charity work leads to population-wide resistance. Nature 2010; 467:82-85; PMID:20811456; http://dx.doi.org/10.1038/nature09354
92. Vega NM, Allison KR, Khalil AS, Collins JJ. Signaling-mediated bacterial persister formation. Nat Chem Biol 2012; 8:431-433; PMID:22426114; http://dx.doi.org/10.1038/nchembio.915
93. Wu Y, Vulic M, Keren I, Lewis K. Role of oxida-tive stress in persister tolerance. Antimicrob Agents Chemother 2012; 56:4922-4926; PMID:22777047; http://dx.doi.org/10.1128/AAC.00921-12
94. Grant SS, Kaufmann BB, Chand NS, Haseley N, Hung D T. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci U S A 2012; 109:12147-12152; PMID:22778419; http://dx.doi.org/10.1073/pnas.1203735109
95. Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 2011; 286:10276-10287; PMID:21193400; http://dx.doi.org/10.1074/jbc. M110.200501
96. Levin BRRD, Rozen DE. Non-inherited antibiotic resistance. Nat Rev Microbiol 2006; 4:556-562; PMID:16778840; http://dx.doi.org/10.1038/nrmi-cro1445
97. Eng RH, Padberg FT, Smith SM, Tan EN, Cherubin CE. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob Agents Chemother 1991; 35:1824-1828; PMID:1952852; http://dx.doi.org/10.1128/AAC.35.9.1824
98. Dahl JL, Kraus CN, Boshoff HI, Doan B, Foley K, Avarbock D, et al. The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A 2003; 100:10026-10031; PMID:12897239; http://dx.doi.org/10.1073/pnas.1631248100
99. Wayne LG, Lin KY. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 1982; 37:1042-1049; PMID:6813266.
100. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002; 43:717-731; PMID:11929527; http://dx.doi.org/10.1046/j.1365-2958.2002.02779.x
101. Xie Z, Siddiqi N, Rubin EJ. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2005; 49:4778-4780; PMID:16251329; http://dx.doi.org/10.1128/AAC.49.11.4778-4780.2005
102. Gold B, Pingle M, Brickner SJ, Shah N, Roberts J, Rundell M, et al. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A 2012; 109:16004-16011; PMID:23012453; http://dx.doi.org/10.1073/pnas.1214188109
103. Dalebroux ZD, Swanson MS. PpGpp: magic beyond RNA polymerase. Nat Rev Microbiol 2012; 10:203-212; PMID:22337166; http://dx.doi.org/10.1038/nrmicro2720
104. Kusser W, Ishiguro EE. Involvement of the relA gene in the autolysis of Escherichia coli induced by inhibitors of peptidoglycan biosynthesis. J Bacteriol 1985; 164:861-865; PMID:3902801.
105. Rodionov DG, Ishiguro EE. Direct correlation between overproduction of guanosine 3',5'-bispyrophosphate (ppGpp) and penicillin tolerance in Escherichia coli. J Bacteriol 1995; 177:4224-4229;PMID:7635809.
106. Nguyen D, Joshi-Datar A, Lepine F, Bauerle E, Olakanmi O, Beer K, et al. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science 2011; 334:982-986; PMID:22096200; http://dx.doi.org/10.1126/science.1211037
107. Costerton JWS, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318-1322; PMID:10334980; http://dx.doi.org/10.1126/science.284.5418.1318
108. Schembri MA, Kjaergaard K, Klemm P. Global gene expression in Escherichia coli biofilms. Mol Microbiol 2003; 48:253-267; PMID:12657059; http://dx.doi.org/10.1046/j.1365-2958.2003.03432.x
109. Otto M. Staphylococcal infections: mechanisms of biofilm maturation and detachment as critical determinants of pathogenicity. Annu Rev Med 2013; 64:175-188; PMID:22906361; http://dx.doi.org/10.1146/annurev-med-042711-140023
110. Kolodkin-Gal I, Romero D, Cao S, Clardy J, Kolter R, Losick R. D-amino acids trigger biofilm disassembly. Science 2010; 328:627-629; PMID:20431016; http://dx.doi.org/10.1126/science.1188628
111. Boles BR, Singh PK. Endogenous oxidative stress produces diversity and adaptability in biofilm communities. Proc Natl Acad Sci U S A 2008; 105:12503-12508; PMID:18719125; http://dx.doi.org/10.1073/pnas.0801499105
112. Landini P. Cross-talk mechanisms in biofilm formation and responses to environmental and physiological stress in Escherichia coli. Res Microbiol 2009; 160:259-266; PMID:19345733; http://dx.doi.org/10.1016/j.resmic.2009.03.001
113. Bink A, Vandenbosch D, Coenye T, Nelis H, Cammue B P, Thevissen K. Superoxide dismutases are involved in Candida albicans biofilm persistence against micon-azole. Antimicrob Agents Chemother 2011; 55:4033-4037; PMID:21746956; http://dx.doi.org/10.1128/AAC.00280-11
114. Lemos JA, Brown TA Jr., Burne RA. Effects of RelA on key virulence properties of planktonic and biofilm populations of Streptococcus mutans. Infect Immun 2004; 72:1431-1440; PMID:14977948; http://dx.doi.org/10.1128/IAI.72.3.1431-1440.2004
115. Anderl JN, Zahller J, Roe F, Stewart PS. Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampicil-lin and ciprofloxacin. Antimicrob Agents Chemother 2003; 47:1251-1256; PMID:12654654; http://dx.doi.org/10.1128/AAC.47.4.1251-1256.2003
116. Häussler S. Biofilm formation by the small colony variant phenotype of Pseudomonas aeruginosa. Environ Microbiol 2004; 6:546-551; PMID:15142242; http://dx.doi.org/10.1111/j.1462-2920.2004.00618.x
117. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000; 407:762-764; PMID:11048725; http://dx.doi.org/10.1038/35037627
118. Mulcahy LR, Burns JL, Lory S, Lewis K. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol 2010; 192:6191-6199; PMID:20935098; http://dx.doi.org/10.1128/JB.01651-09
119. Allison KR, Brynildsen M P, Collins JJ. Heterogeneous bacterial persisters and engineering approaches to eliminate them. Curr Opin Microbiol 2011; 14:593-598; PMID:21937262; http://dx.doi.org/10.1016/j.mib.2011.09.002
120. Brynildsen M P, Winkler JA, Spina CS, Macdonald IC, Collins JJ. Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production. Nat Biotechnol 2013; 31:160-165; PMID:23292609; http://dx.doi.org/10.1038/nbt.2458